Annovis Bio, Inc. announced last patient last visit in the phase II/III study of its lead candidate buntanetap in patients with mild to moderate Alzheimer's disease (AD). A total of 327 patients have successfully concluded the phase II/III trial out of the initial 353 enrolled.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
5.14 USD | -3.93% | -16.04% | -72.57% |
Apr. 30 | Canaccord Genuity Cuts Price Target on Annovis Bio to $26 From $36, Maintains Buy Rating | MT |
Apr. 29 | Sector Update: Health Care Stocks Edge Higher Late Afternoon | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-72.57% | 58.91M | |
+4.23% | 106B | |
+7.02% | 23.47B | |
-14.44% | 21.9B | |
-7.05% | 18.77B | |
-38.55% | 17.85B | |
-9.20% | 16.78B | |
+6.94% | 14.41B | |
+35.80% | 12.86B | |
+317.76% | 8.78B |
- Stock Market
- Equities
- ANVS Stock
- News Annovis Bio, Inc.
- Annovis Bio, Inc. Announces Last Patient Last Visit in Phase II/III Study of Buntanetap in Alzheimer's Disease